Rapid Assessment and Containment of Candida auris Transmission in Postacute Care Settings-Orange County, California, 2019
- PMID: 34487450
- PMCID: PMC10984253
- DOI: 10.7326/M21-2013
Rapid Assessment and Containment of Candida auris Transmission in Postacute Care Settings-Orange County, California, 2019
Abstract
Background: Candida auris, a multidrug-resistant yeast, can spread rapidly in ventilator-capable skilled-nursing facilities (vSNFs) and long-term acute care hospitals (LTACHs). In 2018, a laboratory serving LTACHs in southern California began identifying species of Candida that were detected in urine specimens to enhance surveillance of C auris, and C auris was identified in February 2019 in a patient in an Orange County (OC), California, LTACH. Further investigation identified C auris at 3 associated facilities.
Objective: To assess the prevalence of C auris and infection prevention and control (IPC) practices in LTACHs and vSNFs in OC.
Design: Point prevalence surveys (PPSs), postdischarge testing for C auris detection, and assessments of IPC were done from March to October 2019.
Setting: All LTACHs (n = 3) and vSNFs (n = 14) serving adult patients in OC.
Participants: Current or recent patients in LTACHs and vSNFs in OC.
Intervention: In facilities where C auris was detected, PPSs were repeated every 2 weeks. Ongoing IPC support was provided.
Measurements: Antifungal susceptibility testing and whole-genome sequencing to assess isolate relatedness.
Results: Initial PPSs at 17 facilities identified 44 additional patients with C auris in 3 (100%) LTACHs and 6 (43%) vSNFs, with the first bloodstream infection reported in May 2019. By October 2019, a total of 182 patients with C auris were identified by serial PPSs and discharge testing. Of 81 isolates that were sequenced, all were clade III and highly related. Assessments of IPC identified gaps in hand hygiene, transmission-based precautions, and environmental cleaning. The outbreak was contained to 2 facilities by October 2019.
Limitation: Acute care hospitals were not assessed, and IPC improvements over time could not be rigorously evaluated.
Conclusion: Enhanced laboratory surveillance and prompt investigation with IPC support enabled swift identification and containment of C auris.
Primary funding source: Centers for Disease Control and Prevention.
Figures


Comment in
-
To Each Villain Its Plot: The Case of Candida auris.Ann Intern Med. 2021 Nov;174(11):1622-1623. doi: 10.7326/M21-3456. Epub 2021 Sep 7. Ann Intern Med. 2021. PMID: 34487449 No abstract available.
References
-
- Centers for Disease Control and Prevention. Tracking Candida auris. Accessed at www.cdc.gov/fungal/candida-auris/tracking-c-auris.html on 26 June 2021.
-
- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2019. doi:10.15620/cdc:82532 - DOI
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources